217 related articles for article (PubMed ID: 18794327)
1. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
Yan C; Kepa JK; Siegel D; Stratford IJ; Ross D
Mol Pharmacol; 2008 Dec; 74(6):1657-65. PubMed ID: 18794327
[TBL] [Abstract][Full Text] [Related]
2. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
3. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
4. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
[TBL] [Abstract][Full Text] [Related]
5. Role of NADPH cytochrome P450 reductase in activation of RH1.
Begleiter A; Leith MK; Patel D; Hasinoff BB
Cancer Chemother Pharmacol; 2007 Oct; 60(5):713-23. PubMed ID: 17256129
[TBL] [Abstract][Full Text] [Related]
6. The reductive activation of the antitumor drug RH1 to its semiquinone free radical by NADPH cytochrome P450 reductase and by HCT116 human colon cancer cells.
Hasinoff BB; Begleiter A
Free Radic Res; 2006 Sep; 40(9):974-8. PubMed ID: 17015278
[TBL] [Abstract][Full Text] [Related]
7. The anti-tumour compound, RH1, causes mitochondria-mediated apoptosis by activating c-Jun N-terminal kinase.
Park MT; Song MJ; Oh ET; Lee H; Choi BH; Jeong SY; Choi EK; Park HJ
Br J Pharmacol; 2011 Jun; 163(3):567-85. PubMed ID: 21250978
[TBL] [Abstract][Full Text] [Related]
8. Role of NAD(P)H:quinone oxidoreductase (NQO1) in apoptosis induction by aziridinylbenzoquinones RH1 and MeDZQ.
Nemeikaite-Ceniene A; Dringeliene A; Sarlauskas J; Cenas N
Acta Biochim Pol; 2005; 52(4):937-41. PubMed ID: 15940348
[TBL] [Abstract][Full Text] [Related]
9. Effect of NQO1 induction on the antitumor activity of RH1 in human tumors in vitro and in vivo.
Digby T; Leith MK; Thliveris JA; Begleiter A
Cancer Chemother Pharmacol; 2005 Sep; 56(3):307-16. PubMed ID: 15877230
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxicity of RH1 and related aziridinylbenzoquinones: involvement of activation by NAD(P)H:quinone oxidoreductase (NQO1) and oxidative stress.
Nemeikaite-Ceniene A; Sarlauskas J; Anusevicius Z; Nivinskas H; Cenas N
Arch Biochem Biophys; 2003 Aug; 416(1):110-8. PubMed ID: 12859987
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity of RH1: NAD(P)H:quinone acceptor oxidoreductase (NQO1)-independent oxidative stress and apoptosis induction.
Tudor G; Alley M; Nelson CM; Huang R; Covell DG; Gutierrez P; Sausville EA
Anticancer Drugs; 2005 Apr; 16(4):381-91. PubMed ID: 15746574
[TBL] [Abstract][Full Text] [Related]
12. Preclinical evaluation of the pharmacodynamic properties of 2,5-diaziridinyl-3-hydroxymethyl-6-methyl-1,4-benzoquinone.
Ward TH; Danson S; McGown AT; Ranson M; Coe NA; Jayson GC; Cummings J; Hargreaves RH; Butler J
Clin Cancer Res; 2005 Apr; 11(7):2695-701. PubMed ID: 15814651
[TBL] [Abstract][Full Text] [Related]
13. Expression of human NAD(P)H: quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: effect on the toxicity of antitumor quinones.
Gustafson DL; Beall HD; Bolton EM; Ross D; Waldren CA
Mol Pharmacol; 1996 Oct; 50(4):728-35. PubMed ID: 8863816
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice.
Loadman PM; Phillips RM; Lim LE; Bibby MC
Biochem Pharmacol; 2000 Apr; 59(7):831-7. PubMed ID: 10718341
[TBL] [Abstract][Full Text] [Related]
15. RH1 induces cellular damage in an NAD(P)H:quinone oxidoreductase 1-dependent manner: relationship between DNA cross-linking, cell cycle perturbations, and apoptosis.
Dehn DL; Inayat-Hussain SH; Ross D
J Pharmacol Exp Ther; 2005 May; 313(2):771-9. PubMed ID: 15665137
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity of the bioreductive agent RH1 and its lack of interaction with radiation.
Kim JY; West CM; Valentine H; Ward TH; Patterson AV; Stratford IJ; Roberts SA; Hendry JH
Radiother Oncol; 2004 Mar; 70(3):311-7. PubMed ID: 15064018
[TBL] [Abstract][Full Text] [Related]
17. The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.
Kim JY; Patterson AV; Stratford IJ; Hendry JH
Anticancer Drugs; 2004 Jan; 15(1):71-7. PubMed ID: 15090746
[TBL] [Abstract][Full Text] [Related]
18. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
19. [DT-diaphorase].
Mikami K; Shirakusa T; Tsuruo T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1606-10. PubMed ID: 9309161
[TBL] [Abstract][Full Text] [Related]
20. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.
Knox RJ; Jenkins TC; Hobbs SM; Chen S; Melton RG; Burke PJ
Cancer Res; 2000 Aug; 60(15):4179-86. PubMed ID: 10945627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
